Roth Capital analyst Jotin Marango maintained a Buy rating on Syros Pharmaceuticals (SYRS) today and set a price target of $14. The company’s shares closed yesterday at $6.90.
Marango wrote:
“We continue to believe that the first- in-class CDK7 inhibitor SY-1365 is differentiated mechanistically, and based on its preclinical and clinical portfolio so far we expect it to be active and differentiated clinically.”
According to TipRanks.com, Marango ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.2% and a 37.0% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Aimmune Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Syros Pharmaceuticals with a $11.50 average price target, implying a 66.7% upside from current levels. In a report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.86 and a one-year low of $5.17. Currently, Syros Pharmaceuticals has an average volume of 140.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.
